Interestingly, three SCLC cell lines with c-MYC amplification, including H82, H2171 and H446, had the lowest EC50 to dinaciclib, which is consistent with a recent identification of CDK9 inhibition as a therapeutic strategy for c-MYC-overexpressing hepatocellular carcinoma37. Here, CDK9 is linked to small cell lung carcinoma.